| Iatrogenic myelomonocytic leukemia following melphalan treatment of scleromyxedema. | |
| | |
MedLine Citation:
|
PMID: 3470169 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
We report the case of a patient with scleromyxedema with abnormal monoclonal gamma globulin of the kappa type who was treated with melphalan (Alkeran), an alkylating agent. After nine and one-half years of therapy, the patient showed myelomonocytic leukemia. The risk of secondary malignancies must be considered when weighting the benefits and risks of melphalan treatment. |
| | |
Authors:
|
F Helm; T N Helm |
Related Documents
:
|
21524949 - Small-incision orbicularis-levator fixation technique: a modified double-eyelid blephar... 19950129 - Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence s... 282809 - Leukemia in radiation-treated patients: cytogenetic studies in eight cases. 18061959 - A correlation study of immunophenotypic, cytogenetic, and clinical features of 180 aml ... 10678699 - Large plaque parapsoriasis: clinical and genotypic correlations. 20633929 - Improvement of the who classification-based prognostic scoring system (wpss) by includi... 12561149 - Causes of early post carotid endartectomy stroke in a recent series: the increasing imp... 19685419 - The patient with asymptomatic shortened cervix at 23 to 28 weeks: is delivery imminent? 2079469 - Aetiology of diabetic foot ulceration. |
Publication Detail:
|
Type: Case Reports; Journal Article |
Journal Detail:
|
Title: Cutis; cutaneous medicine for the practitioner Volume: 39 ISSN: 0011-4162 ISO Abbreviation: Cutis Publication Date: 1987 Mar |
Date Detail:
|
Created Date: 1987-05-12 Completed Date: 1987-05-12 Revised Date: 2009-11-11 |
Medline Journal Info:
|
Nlm Unique ID: 0006440 Medline TA: Cutis Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 219-23 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Diabetes Mellitus, Type 1 / complications Humans Leukemia, Myeloid / chemically induced* Male Melphalan / adverse effects* Paraproteinemias / blood, complications* Scleroderma, Systemic / complications, drug therapy, physiopathology* |
| Chemical | |
Reg. No./Substance:
|
148-82-3/Melphalan |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Elimination of enoxacin in renal disease.
Next Document: Selective repression of RNA polymerase II by microinjected phosvitin.